Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

TNG260

Small molecule · Inhibitor of HDAC1 · developed by Tango Therapeutics

Phase 1/2 Most advanced trial
TNGX Developer
1 Registered trials

What is TNG260?

TNG260 is an orally bioavailable small molecule that binds the CoREST complex and inhibits the catalytic activity of HDAC1. Its inhibition increases histone acetylation and alters gene expression, with potential to reverse immune evasion linked to STK11 loss-of-function mutations. It is studied in non-small cell lung cancer and solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
HDAC1, CoREST complex (RCOR1) (binding partner it blocks)
Mechanism
Inhibitor of HDAC1
Pathways
histone deacetylation, chromatin remodeling, gene expression regulation, immune checkpoint inhibitor resistance
Therapy area
Oncology
Developer
Tango Therapeutics, Inc. (TNGX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05887492 Phase 1/2 Non Small Cell Lung Cancer Active not recruiting TNGX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Lung AdenocarcinomaLung CancerNon Small Cell Lung CancerSolid Tumors, Adult

Other drugs acting on HDAC1

More from Tango Therapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the TNGX page.

Follow TNGX, the company behind TNG260

See TNGX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TNGX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.